ArticleInternational dental journal2026
Baicalin Alleviates LPS-Induced Apoptosis of Periodontal Ligament Cells Via Inhibiting Endoplasmic Reticulum Stress.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to investigate the effect of baicalin (BA) on Porphyromonas gingivalis lipopolysaccharide (Pg-LPS)-induced apoptosis in human periodontal ligament cells (hPDLCs) and to explore its underlying mechanisms using a periodontitis mouse model.
methodsIn vitro, the effects of BA on proliferation, apoptosis, and ER stress in Pg-LPS-induced hPDLCs were assessed using CCK-8, immunofluorescence staining, flow cytometry and Western blot. Molecular docking and molecular dynamics (MD) simulations were first conducted to predict the interaction between BA and PERK. The involvement of the PERK pathway was subsequently examined using the activator CCT020312 (CCT) and the inhibitor GSK2606414 (GSK). In vivo, a ligature-induced mouse periodontitis model was established to evaluate BA's therapeutic effects on periodontal tissue.
resultsBA promoted hPDLCs proliferation and inhibited apoptosis by regulating BAX, Cleaved-Caspase3, and Bcl-2 expression. It reduced ER stress by decreasing the expression of GRP78 and PERK, with no significant effect on the expression of IRE1α and ATF6. Consistently, docking and MD simulations supported a stable interaction between BA and PERK (Glide gscore -7.98; stable RMSD). Furthermore, BA suppressed the PERK/eIF2α/ATF4/CHOP pathway, with GSK enhancing its protective effects. In vivo, BA reduced alveolar bone resorption and apoptosis in periodontitis mice, with the BA-GSK combination providing the strongest protection.
conclusionBA shows therapeutic potential for periodontitis by inhibiting ER stress - mediated apoptosis and protecting periodontal tissue.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.